When it comes to infant nutrition, one of the most challenging challenges that new mothers and their babies face is one of the most difficult challenges in the world. On the other hand, consuming the appropriate foods can help facilitate the development of a wholesome microbiota in the gut and strengthen the immune system.
Research has shown that a combination of probiotics and HMO can mimic breastmilk changes and encourage bifidobacteria’s dominance, thereby fostering a more robust gut environment and immune defenses. This has been demonstrated by developing a combination of probiotics and HMO.
HMO, which stands for human milk oligosaccharides, is a prebiotic carbohydrate responsible for providing the beneficial bacteria in the intestines with the required nourishment. These are chains of sugars that are not digestible and travel to the large intestine, where they are absorbed by bacteria that are beneficial to the body. Chains of sugars are similar to carbohydrates. After that, these bacteria convert them into various metabolites that are advantageous to the body when broken down.
More than one hundred different HMO structures can be found in human breast milk, and the levels of these prebiotics change throughout the lactation stages.
More than one hundred different HMO structures can be found in human breast milk, and the levels of these prebiotics change throughout the lactation stages. Human breast milk contains a wide variety of vitamins and minerals. Following lacto-Neotetraose (LNnT), difucosyl lacto-Neotetraose, and 3′-sialyllactose (6’SL) as the HMO that is found in the most significant quantity is 2′-fucosyllactose (2’FL), which is the third most abundant HMO.
The presence of the gene that is responsible for the production of the enzyme Fucosyltransferase 2 (FUT2), which plays a role in the formation of HMOs, is one of the most critical factors that contribute to the differences in HMO levels between infants who are breastfed. This gene is responsible for the formation of HMOs. Compared to the levels of 2’FL and all a-fucosylated oligosaccharides found in the breast milk of other infants, the levels of these substances in the breast milk of infants whose mothers do not possess this gene are significantly lower.
Several studies have shown that infants who are deficient in FUT2 also experience a delay in the establishment of their microbiome, which is abundant in bifidobacteria. This has been demonstrated by several studies. The presence of complex oligosaccharides in these individuals’ stools, such as difucosyl-LNT and a-fucosyl-6’SL, is less common than in other individuals. Furthermore, they are at a greater risk of developing an allergy to cow’s milk than the general population.
The result was the development of a revolutionary formulation, Sinergity. This formulation combined the benefits of this combination of probiotics and HMOs.
Considering these findings, researchers at Nestle concluded that a specific strain of Bifidobacterium, B. infantis LMG11588, possessed the capacity to absorb and metabolize HMOs effectively. Consequently, this made it possible for the strain to consume HMOs in a selective manner and produce key beneficial metabolites comparable to those commonly found in nursing environments.
The result was the development of a revolutionary formulation, Sinergity. This formulation combined the benefits of this combination of probiotics and HMOs. The formulation contains six different concentrations of human milk oligosaccharides, including 2′-FL, LNT, LNnT, 3′-SL, and 6’SL. Additionally, the probiotic strain is incorporated into the formulation.
After being combined in a base of prebiotic inulin, these components are subjected to spray drying to produce a powder. This process is repeated until the powder is produced. The end result is a product that can be incorporated into any existing formulation. This product contributes to the stimulation and maintenance of a diverse microbial community in the gut, and it can be incorporated into any formulation.
Because of the synergy between these factors, preterm infants receive an unrivaled level of protection and a more natural gut flora because they are born prematurely.
Additionally, this new formulation includes a specific strain of Bifidobacterium shown to have a high capacity to metabolize 2′-FL in addition to other oligosaccharides found in human milk, according to research. Because of the synergy between these factors, preterm infants receive an unrivaled level of protection and a more natural gut flora because they are born prematurely.
It is a significant step forward in the research that has been done to understand how the microbiome influences health and the most effective ways to maintain it. Introducing this one-of-a-kind formulation represents a significant step forward in this research. It is the only infant formula with a patented combination of a probiotic and an HMO, making it a truly innovative approach to developing a robust immune system and promoting a strong and healthy microbiota in the stomach. In particular, it is the only formula containing both ingredients. This is an essential step that must be taken to establish a foundation for physical well-being throughout one’s entire life.
